Pay to Marwadi

Company Profile

METROPOLIS HEALTHCARE LTD.

NSE : METROPOLISBSE : 542650ISIN CODE : INE112L01020Industry : Hospital & Healthcare ServicesHouse : Metropolis
BSE1790.85-17.65 (-0.98 % )
PREV CLOSE (Rs.) 1808.50
OPEN PRICE (Rs.) 1806.80
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2766
TODAY'S LOW / HIGH (Rs.)1779.15 1815.25
52 WK LOW / HIGH (Rs.)1209.25 1935
NSE1790.40 -19.05 (-1.05 % )
PREV CLOSE(Rs.) 1809.45
OPEN PRICE (Rs.) 1804.50
BID PRICE (QTY) 1790.40 (95 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 89940
TODAY'S LOW / HIGH(Rs.) 1778.55 1817.40
52 WK LOW / HIGH (Rs.)1209.25 1933.5

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.45
TTM EPS (Rs.) 24.21
P/E Ratio 73.96
Book Value (Rs.) 198.90
Face Value (Rs.) 2
MCap (Rs. in Mn) 91743.11
Price/Earning (TTM) 43.32
Price/Sales (TTM) 8.53
Price/Book (MRQ) 9.00
PAT Margin (%) 13.03
ROCE (%) 19.87
Incorporation Year : 2000

Management Info :

Sushil Kanubhai Shah - Chairman Ameera Sushil Shah - Managing Director

Registered Office :

Address : 4th Floor, East Wing, Plot-254 B,Nirlon House, Dr. Annie Besant Road,Worli,
Mumbai,
Maharashtra-400030

Phone : 022 6258 2810 / 8422 801 801

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE
NEWS More
30Apr04-30-2024$Metropolis Healthcare informs about disclosure Metropolis Healthcare inform

Pursuant to Regulation 30 of the Listing Regulations and in continuation to itsletter dated August 14, 2023, Metropolis Healthcare has informed that the suit filed by Metropolis Bramser Lab Services (Mtius) (‘Metropolis Bramser’, step-down WOS of the Company) before the Supreme Court of Mauritius has been dismissed. The details as required under SEBI Circular No SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13 July 2023 are enclosed.

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the Listing Regulations and in con..
15Apr04-15-2024$ Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Announcement under Regulati
Intimation of allotment of equity shares under Metropolis Healthcare Limited Restrictive Stock Unit Plan -2020
Intimation of allotment of equity shares under Metropolis Healt..
12Apr04-12-2024$Metropolis Healthcare reports 15% growth in core business revenue during Q4FY24 Metropolis Healthcare report

Metropolis Healthcare has reported around 15% growth Year-on-Year (Y-o-Y) in core business revenue during fourth quarter of FY24. Its core revenue growth was driven by volume growth around 8% and Revenue Per Patient (RPP) growth at 7% YoY for Q4FY24. RPP growth was largely driven by growth in speciality tests segment, premium wellness segment and price increase. The company’s Business-to-Consumer (B2C) revenue grew at around 18% Y-o-Y for Q4FY24. Meanwhile, the company has become debt-free in Q4FY24.  

Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.

Metropolis Healthcare has reported around 15% growth Year-on-Ye..
12Apr04-12-2024$Metropolis Healthcare soars on reporting 15% growth in core business revenue during Q4FY24 Metropolis Healthcare soars

Metropolis Healthcare is currently trading at Rs. 1883.30, up by 83.95 points or 4.67% from its previous closing of Rs. 1799.35 on the BSE.

The scrip opened at Rs. 1864.00 and has touched a high and low of Rs. 1935.00 and Rs. 1850.55 respectively. So far 267666 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1,935.00 on 12-Apr-2024 and a 52 week low of Rs. 1209.25 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 1935.00 and Rs. 1679.30 respectively. The current market cap of the company is Rs. 9647.55 crore.

The promoters holding in the company stood at 49.74%, while Institutions and Non-Institutions held 42.39% and 7.87% respectively.

Metropolis Healthcare has reported around 15% growth Year-on-Year (Y-o-Y) in core business revenue during fourth quarter of FY24. Its core revenue growth was driven by volume growth around 8% and Revenue Per Patient (RPP) growth at 7% YoY for Q4FY24. RPP growth was largely driven by growth in speciality tests segment, premium wellness segment and price increase. The company’s Business-to-Consumer (B2C) revenue grew at around 18% Y-o-Y for Q4FY24. Meanwhile, the company has become debt-free in Q4FY24.  

Metropolis Healthcare is engaged in the business of providing pathology and related healthcare services.

Metropolis Healthcare is currently trading at Rs. 1883.30, up b..
14Mar03-14-2024$Metropolis Healthcare informs about disclosure Metropolis Healthcare inform
Metropolis Healthcare has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund & Others.

The above information is a part of company’s filings submitted to BSE. 
Metropolis Healthcare has informed that the exchange has receiv..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit266.971389.46
Gross Profit 346.31 1789.44
Operating Profit 640.142905.92
Net Sales 2694.0910660.41
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
RainbowChildrenS Med (BSE)
 1461.55 (5.43%)
M.Cap ( in Cr)
14834.98
Apollo Hospital Ent. (BSE)
 6009.00 (0.89%)
M.Cap ( in Cr)
86400.20
Jupiter Life Line (BSE)
 1223.15 (1.41%)
M.Cap ( in Cr)
8019.71
HealthcareGlobal (BSE)
 369.50 (4.26%)
M.Cap ( in Cr)
5146.75
Fortis Healthcare (BSE)
 451.70 (2.52%)
M.Cap ( in Cr)
34101.46
Shareholding Pattern More
NON-INSTITUTION 6.57 %
PROMOTERS 49.67 %
FI/BANKS/INSURANCE 3.29 %
MUTUAL FUNDS/UTI 21.31 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes